Type 2 diabetes: summary of updated NICE guidance
BMJ
.
2022 May 18:377:o775.
doi: 10.1136/bmj.o775.
Authors
Gregory M Moran
1
,
Chirag Bakhai
2
,
Soon H Song
3
,
Juliana Chizo Agwu
4
;
Guideline Committee
Affiliations
1
National Institute for Health and Care Excellence (NICE), City Tower, Piccadilly Plaza, Manchester M1 4BT, UK Gregory.moran@nice.org.uk.
2
Bedfordshire, Luton and Milton Keynes Clinical Commissioning Group, Capability House, Bedford MK45 4HR, UK.
3
Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield S5 7AU, UK.
4
Sandwell and West Birmingham NHS Trust, Sandwell General Hospital, West Bromwich B71 4HJ, UK.
PMID:
35584815
DOI:
10.1136/bmj.o775
No abstract available
MeSH terms
Diabetes Mellitus, Type 2* / therapy
Humans
Hypoglycemic Agents / therapeutic use
Substances
Hypoglycemic Agents